Obinutuzumab for the management of immune-mediated glomerular diseases

Obinutuzumab is currently being investigated as an alternative anti-CD20 therapy for renal diseases where rituximab demonstrates limitations. Although rituximab is established as a first-line treatment for primary MN and AAV, its efficacy in podocytopathies and LN remains debated. This strategy remains promising, even in light of suboptimal or disappointing outcomes seen with other agents targeting the same molecular pathways.